To assess the clinical relevance of these findings, the predictive power of IL-1β on clinical outcomes and treatment response in patients with esophageal SCC was evaluated using immunohistochemistry (IHC) analysis. The gene discussed is IL1B; the disease is esophageal squamous cell carcinoma.